Furthermore, findings from a multicohort, phase I KEYNOTE-028 study conducted on patients with PD-L1-positive NETs revealed that pembrolizumab treatment yielded an ORR of 12.0% for those with carcinoid tumors and 6.3% for those with well- or moderately-differentiated pNETs [148]. This evidence concerns the gene CD274 and carcinoid tumor.